Generics BulletinOrganon believes there is “considerable growth potential” for the Tofidence (tocilizumab-bavi) biosimilar to Genentech’s Actemra, after acquiring rights in the US for the product from Biogen, in a dea
Generics BulletinDr Reddy’s has gained rights to a pair of proposed Stelara (ustekinumab) and Simponi (golimumab) biosimilars in multiple markets in south-east Asia, after striking an exclusive commercialization agree
ScripAs China’s immuno-oncology market adapts to the ever-growing ranks of homegrown PD-1/L1-targeting agents, SinoCellTech has received approval for what will be the 17th product in the sector - but the f
Generics BulletinBio-Thera Solutions has matched Alvotech with the European Medicines Agency accepting for review the Chinese manufacturer’s proposed biosimilar to Johnson & Johnson’s Simponi (golimumab) once-mont